secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001437749-26-010967
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia files FDA meeting request for CardiAMP HF accelerated approval; subgroup shows risk reduction
--------------------------------------------------------------------------------

- Submitted CardiAMP HF clinical study data to FDA; meeting expected Q2 2026 under Breakthrough Designation.
- Subgroup with elevated biomarkers showed 47% relative risk reduction in all-cause cardiac death.
- Same subgroup had 37% relative risk reduction in non-fatal major adverse cardiac events (stroke, MI, hospitalization).
- Quality of life improvements were statistically significant (p=0.04) in the elevated-biomarker subgroup.
- Seeking accelerated approval for CardiAMP System in ischemic HFrEF.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774926010967/0001437749-26-010967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774926010967/bcda20260402_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-010967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer